Board of Directors
Our Board of Directors is comprised of an experienced mix of professionals from
the research and life science community, as well as the real estate and financial
Their breadth of expertise and perspectives has proven invaluable as BioMed Realty
has grown and expanded across the country.
Board of Directors
Daniel M. Bradbury
Daniel M. Bradbury has been a director since January 2013. Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm. He served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin’s President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003, and other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury was a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, holding a number of sales and marketing positions. Mr. Bradbury is currently a member of the boards of directors of Illumina, Inc., Geron Corporation, Corcept Therapeutics Inc. and Castle Biosciences, Inc. and the board of trustees for the Keck Graduate Institute of the Claremont Colleges. Mr. Bradbury also serves on the Advisory Council of the University of California San Diego’s Rady School of Management, and the University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Mr. Bradbury is the chair of our Nominating & Corporate Governance Committee and a member of our Compensation Committee.